Andreas Hüttmann

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

Steven M. Horwitz, Owen A. O’Connor, Barbara Pro et al. · The Lancet · 2018 · 707 citations · Full text

Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma

David M. Kurtz, Florian Scherer, Michael C. Jin et al. · Journal of Clinical Oncology · 2018 · 472 citations · Full text

Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation

Nicola Gökbuget, Daniel Stanze, Joachim Beck et al. · Blood · 2012 · 451 citations · Full text

Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial

Christoph Röllig, Hubert Serve, Andreas Hüttmann et al. · The Lancet Oncology · 2015 · 395 citations · Full text

Sorafenib Versus Placebo, Hematological Malignancy, Oncology +9

PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group

Peter Borchmann, Helen Goergen, Carsten Kobe et al. · The Lancet · 2017 · 372 citations

Positron Emission Tomography, Advanced-stage Hodgkin, Lymphoid Neoplasia +9